STOCK TITAN

Wellington reports 0% stake in Beta Bionics (BBNX) in 13G/A

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Beta Bionics, Inc. (BBNX) received an amended Schedule 13G from Wellington Management Group LLP and related entities showing they no longer hold a reportable stake in the company. As of 12/31/2025, Wellington Management Group LLP, Wellington Group Holdings LLP, and Wellington Investment Advisors Holdings LLP each report 0.00 shares of Beta Bionics common stock, representing 0.0% of the outstanding class, with no sole or shared voting or dispositive power.

The filing explains that any Beta Bionics shares covered by this schedule are owned of record by clients of various Wellington investment advisers, and no single client is known to hold more than five percent of the common stock. Wellington also certifies that any securities were acquired and held in the ordinary course of business and not for the purpose of changing or influencing control of Beta Bionics.

Positive

  • None.

Negative

  • None.

Insights

Wellington and affiliates now report 0% ownership of Beta Bionics common stock.

Wellington Management Group LLP and its related entities disclose that, as of 12/31/2025, they beneficially own 0.00 shares of Beta Bionics common stock, representing 0.0% of the class. They report no sole or shared voting or dispositive power over any shares.

The securities referenced are held of record by clients of several Wellington investment advisers, but the filing states that no client is known to have rights over more than five percent of the class. Wellington characterizes its holdings as acquired and held in the ordinary course of business and not for influencing control of the company.

This amendment signals the transition of Wellington’s reportable ownership position in Beta Bionics to below the five percent threshold. Future ownership visibility will depend on whether any single client or manager again exceeds that reporting level and files a new beneficial ownership statement.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Wellington Management Group LLP
Signature:Taisia Lowe
Name/Title:Regulatory Analyst
Date:02/10/2026
Wellington Group Holdings LLP
Signature:Taisia Lowe
Name/Title:Regulatory Analyst
Date:02/10/2026
Wellington Investment Advisors Holdings LLP
Signature:Taisia Lowe
Name/Title:Regulatory Analyst
Date:02/10/2026

FAQ

What does Wellington’s Schedule 13G/A filing say about its Beta Bionics (BBNX) ownership?

The amended Schedule 13G/A shows Wellington Management Group LLP and related entities now report beneficial ownership of 0.00 Beta Bionics common shares, representing 0.0% of the class as of December 31, 2025, meaning they no longer have a reportable stake under the five percent threshold.

Who are the reporting persons in the Beta Bionics (BBNX) Schedule 13G/A amendment?

The filing lists Wellington Management Group LLP, Wellington Group Holdings LLP, and Wellington Investment Advisors Holdings LLP as reporting persons. Each entity reports 0.00 shares beneficially owned, 0.0% of the common stock class, and no sole or shared voting or dispositive power over Beta Bionics shares.

How many Beta Bionics (BBNX) shares do Wellington entities report owning?

Wellington Management Group LLP and its related entities report owning 0.00 shares of Beta Bionics common stock. They also disclose 0.0% of the class and no sole or shared voting or dispositive power, indicating they no longer hold a reportable ownership position in the company’s common stock.

Who actually holds the Beta Bionics (BBNX) shares referenced in Wellington’s filing?

The securities referenced are owned of record by clients of various Wellington investment advisers. The filing states these clients have dividend and sale rights, but no individual client is known to have such rights over more than five percent of Beta Bionics’ common stock, based on Wellington’s disclosures.

Does Wellington intend to influence control of Beta Bionics (BBNX) according to this filing?

Wellington certifies that any Beta Bionics securities were acquired and are held in the ordinary course of business. The filing states they were not acquired and are not held for changing or influencing control of Beta Bionics or in connection with any control-related transaction.

What is the key ownership threshold mentioned in the Beta Bionics (BBNX) Schedule 13G/A?

The filing emphasizes the five percent ownership threshold. Wellington reports beneficial ownership of 0.0% of Beta Bionics’ common stock and notes that no client is known to have rights to more than five percent of the class, which explains why the position is now reported below that level.
Beta Bionics, Inc.

NASDAQ:BBNX

BBNX Rankings

BBNX Latest News

BBNX Latest SEC Filings

BBNX Stock Data

610.62M
43.46M
6.49%
104.92%
7.16%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
IRVINE